What is CJC-1295?
CJC-1295 is a growth-hormone-releasing-hormone analogue. The foundational human trials studied a long-acting preparation and measured endocrine responses.
Video overview · 3:09
CJC-1295 + Ipamorelin: A Safe, Natural Growth Hormone Boost? What the Evidence Shows
What each peptide is, what the short human studies measured, why no published trial has tested the pair together, the serious adverse events FDA has noted, and their FDA and anti-doping status.
Narrated with an AI voice from this profile's sources; education only, no dosing.
Read the transcript
CJC-1295 and ipamorelin are two lab-made peptides often sold together, marketed as a safe, natural way to boost growth hormone. They do raise growth hormone in people. The rest of that claim is a different story.
CJC-1295 is a lab-made version of the hormone that tells the pituitary gland to release growth hormone. The version tested in people binds to a blood protein, so it lasts about eight days. Sellers also use the name for a version without that feature, which published human trials did not test. Ipamorelin is a five amino acid peptide that acts on the ghrelin receptor, a different trigger.
CJC-1295 signals the pituitary, ipamorelin triggers a growth-hormone pulse, and growth hormone and a related hormone, IGF-1, rise. That much has been measured. Whether it leads to more muscle, faster recovery or slower aging has not been shown. A hormone level is a lab result, not a health outcome.
In two 2006 trials in healthy adults, a single exposure to CJC-1295 raised growth hormone two- to ten-fold for six days or more. In healthy men, ipamorelin produced a single growth-hormone burst, and it cleared with a half-life of about two hours. But when ipamorelin was tested against a real medical goal, speeding recovery after bowel surgery in a hundred and fourteen patients, it did not beat placebo.
And the combination? We found no published human trial of CJC-1295 and ipamorelin used together. A 2026 review notes the pair's only muscle findings come from mice, and a 2026 sports-medicine review found that claims of better recovery and performance are not backed by human trials.
Now the safe part. The FDA says it has identified serious adverse events with CJC-1295, including a faster heart rate and a body-wide reaction that widens blood vessels. For ipamorelin, it cites a published study in which serious adverse events, including a death, were identified with intravenous use. Neither is FDA approved, both are banned in sport, and the human studies lasted weeks, so long-term safety is unknown.
So, do they raise growth hormone? Supported, in short human studies. Is the combination proven? There is no published trial. Are they natural? No: they are engineered drugs, and ipamorelin contains amino acids that do not occur in human proteins. Are they safe? Unproven. PepsRadar's claim check rates the whole claim partly supported.
The bottom line: CJC-1295 and ipamorelin raise growth hormone, but no trial shows the pair improves health, the FDA has flagged serious adverse events, and neither is approved. For the full claim check and every source, see PepsRadar dot com.
Biological role or research focus
Stimulation of growth hormone and IGF-1.
CJC-1295 with DAC and products called “CJC no DAC” should not be treated as the same study compound.
Names you may encounter
CJC 1295 · CJC1295
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Long-acting GHRH analogue
- Main research area
- Growth hormone and IGF-1 signaling
- Evidence featured
- Human pharmacology trials
- Source check
- October 4, 2026
Quick answers
- Is CJC-1295 FDA approved?
- No. No FDA-approved drug contains CJC-1295. Source ↗
- Is CJC-1295 safe?
- CJC-1295 is an unapproved growth-hormone-releasing analogue. Small, short trials reported no serious reactions, but FDA cites serious events including a faster heart rate and a body-wide vasodilation reaction. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is CJC-1295 banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.4 Growth hormone releasing factors). Source ↗
- Has the FDA taken action over CJC-1295?
- Yes. Our records list 1 FDA action naming it, most recently on April 1, 2020: FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing CJC 1295 among bulk substances that are not eligible for 503A compounding exemptions. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Long-acting CJC-1295 (2006) | Human pharmacology trials | Healthy adults aged 21–61. |
| Growth-hormone pulsatility after long-acting CJC-1295 (2006) | Human physiology study | Healthy men aged 20–40 years. |
Claim check
Partly supported Are CJC-1295 and ipamorelin a safe, natural way to boost growth hormone?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human pharmacology trials · 2006
Long-acting CJC-1295
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
- Population / model
- Healthy adults aged 21–61.
- Study design
- Two randomized, blinded, placebo-controlled ascending-dose studies lasting 28 and 49 days.
- Main finding
- Mean growth hormone rose two- to tenfold for at least six days; IGF-1 rose 1.5- to threefold for nine to eleven days after a single exposure. The estimated half-life was 5.8–8.1 days.
- Limits & context
- The endpoints were hormone concentrations. These were studies of long-acting CJC-1295, not proof of muscle gain or equivalence to products labeled “CJC no DAC.”
Human physiology study · 2006
Growth-hormone pulsatility after long-acting CJC-1295
Did longer-lasting stimulation preserve the pattern of GH pulses?
- Population / model
- Healthy men aged 20–40 years.
- Study design
- Overnight blood sampling every 20 minutes before and one week after a single administration of the albumin-binding, long-acting CJC-1295 preparation.
- Main finding
- GH pulses persisted. Trough GH increased markedly, while mean GH and IGF-I also increased. Pulse frequency and magnitude were not significantly altered in the reported assessment.
- How to read it
- A change in hormone secretion is a biological measurement. It does not itself show improved strength, injury recovery, body composition, or quality of life.
- Limits & context
- Short physiological follow-up in healthy men. These results concern the long-acting albumin-binding compound and should not be assigned automatically to products called “CJC without DAC.”
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
1 registered study names CJC-1295 as an intervention; 0 are recruiting or under way, 0 have not started recruiting yet, 0 completed and 1 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
| Study | Status | Phase | Start | People |
|---|---|---|---|---|
| A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity NCT00267527 · ConjuChem | Terminated | Phase 2 | 2005-12 | 120 |
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination.
Search additional PubMed records ↗Risks & interactions
CJC-1295 is an unapproved growth-hormone-releasing analogue. Small, short trials reported no serious reactions, but FDA cites serious events including a faster heart rate and a body-wide vasodilation reaction.
Two small randomized trials in healthy adults lasting up to seven weeks, and a short physiology study, reported no serious adverse reactions. They were too small and brief to detect uncommon or long-term harms of sustained GH and IGF-1 elevation.
Unassessed: little human safety data
Take extra care with: Heart or blood pressure problems
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Serious risks
- FDA: increased heart rate and systemic vasodilatory reaction reported
- FDA: possible immune reactions (immunogenicity) and peptide-impurity problems with compounded products
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks (category 2) ↗ · CJC-1295 trials in healthy adults (2006) ↗ · GH pulsatility during CJC-1295 stimulation (2006) ↗
Safety evidence & remaining uncertainty
FDA reports cardiovascular reactions and limited clinical data. Small, short trials reporting no serious events cannot rule out uncommon or long-term harms.
Source: FDA · Peptide compounding safety concerns ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "CJC-1295". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.2.4 Growth hormone releasing factors
Named explicitly as a GHRH analogue ("CJC-1295"). source
FDA actions
- FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing CJC 1295 among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source
Other notes
- Australia, October 2026: Victorian coroner David Ryan found that actor Richard Norton's death in March 2025 was triggered by injecting compounded CJC-1295 and ipamorelin prescribed by a doctor. Norton had told a clinic nurse he was taking double the prescribed dose. The coroner recommended the TGA review the benefits and safety risks of peptides such as CJC-1295 and ipamorelin and consider further restrictions. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
The studies establish a pharmacodynamic response in healthy adults. They do not establish injury treatment, muscle-building benefit, or an anti-aging indication. Product names containing “no DAC” need separate identity and study checks.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
It stimulates the pituitary growth-hormone pathway, followed by increased IGF-1. Prolonged hormone exposure is central to the studied molecule; a similarly named short-acting product is not automatically equivalent.
Molecular structure
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- CJC-1295 with DAC and products called “CJC no DAC” should not be treated as the same study compound.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Does the published half-life apply to “CJC no DAC”?
It should not be assumed to. The trial studied long-acting CJC-1295, not every material sold under the CJC name.
Does higher IGF-1 prove better recovery?
No. It is an endocrine response. Recovery, function, and adverse outcomes must be measured separately.
What does the Growth-hormone pulsatility after long-acting CJC-1295 study show, and what does it not?
A change in hormone secretion is a biological measurement. It does not itself show improved strength, injury recovery, body composition, or quality of life. Short physiological follow-up in healthy men. These results concern the long-acting albumin-binding compound and should not be assigned automatically to products called “CJC without DAC.”
References & editorial record
- FDA · Compounding safety concerns ↗
- CJC-1295 trials in healthy adults (2006) ↗
- Ionescu and Frohman · JCEM · 2006 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
PUT THE EVIDENCE IN CONTEXT
Research guides
RESEARCH FIELD GUIDE
CJC-1295 and ipamorelin: a hormone signal is only part of the story
Why GH and IGF-I measurements, product identity, and a negative postoperative trial belong in the same research discussion.
Read the guide →RESEARCH FIELD GUIDE
Is ipamorelin legal? Side effects, FDA status and what the studies show
Ipamorelin is not an approved drug anywhere in the US, the FDA has flagged it as a compounding safety risk, and it was left out of the 2026 HHS peptide policy. What it is, the only two human studies, the side-effect and safety concerns, and why it is banned in sport.
Read the guide →

